MoonLake Immunotherapeutics (MLTX) Cash & Equivalents (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Cash & Equivalents of $298.5 million for Q1 2026, up 9.91% year-over-year from $271.6 million in Q1 2025, and down 10.77% quarter-over-quarter from $334.5 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Cash & Equivalents (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $298.5 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 9.91% year-over-year to $298.5 million; the TTM figure through Mar 2026 stood at $298.5 million (up 9.91% YoY), while the FY2025 annual figure was $334.5 million, up 85.4% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $298.5 million, down from $334.5 million in the prior quarter.
- The five-year high for Cash & Equivalents was $501.8 million in Q2 2023, with the low at $23336.0 in Q1 2022.
- The 5-year median for Cash & Equivalents is $312.4 million (2023), against an average of $270.1 million.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 98.01% in 2022, then soared 214714.87% in 2023.
- MoonLake Immunotherapeutics' Cash & Equivalents stood at $39.5 million in 2022, then jumped by 1042.04% to $451.2 million in 2023, then tumbled by 60.01% to $180.4 million in 2024, then surged by 85.4% to $334.5 million in 2025, then decreased by 10.77% to $298.5 million in 2026.
- Business Quant data shows MLTX's Cash & Equivalents at $298.5 million in Q1 2026, $334.5 million in Q4 2025, and $350.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 477.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 477.91 Mn |
| Mar 31, 2026 | 298.49 Mn |
| Dec 31, 2025 | 334.52 Mn |
| Sep 30, 2025 | 350.74 Mn |
| Jun 30, 2025 | 306.68 Mn |
| Mar 31, 2025 | 271.57 Mn |
| Dec 31, 2024 | 180.43 Mn |
| Sep 30, 2024 | 375.66 Mn |
| Jun 30, 2024 | 342.79 Mn |
| Mar 31, 2024 | 458.44 Mn |
| Dec 31, 2023 | 451.17 Mn |
| Sep 30, 2023 | 318.17 Mn |
| Jun 30, 2023 | 501.79 Mn |
| Mar 31, 2023 | 50.13 Mn |
| Dec 31, 2022 | 39.51 Mn |
| Sep 30, 2022 | 41.20 Mn |
| Mar 31, 2022 | 23,336.00 |
| Dec 31, 2021 | 8.04 Mn |
| Sep 30, 2021 | 1.03 Mn |
| Jun 30, 2021 | 1.10 Mn |